• 한국동물학회:학술대회논문집
• /
• 한국동물학회 2000년도 한국생물과학협회 학술발표대회
• /
• pp.193-193
• /
• 2000

No Abstract, See Full Text

• 한국동물학회:학술대회논문집
• /
• 한국동물학회 1999년도 한국생물과학협회 학술발표대회
• /
• pp.174.2-174
• /
• 1999

No Abstract, See Full Text

• Tuberculosis and Respiratory Diseases
• /
• 제53권3호
• /
• pp.349-353
• /
• 2002

여러 국내외 논문에서 hormone 치료는 우수한 효과를 나타내었으나 치료 종료 후 객혈이 다시 발생하여 추가적인 수술을 받는 경우가 많았으며, GnRH analogue의 장점에도 불구하고 hormone 치료로 완치된 예는 대부분 danazol에 의한 경우가 많았다. 저자들이 경험한 환자는 월경과 동반된 객혈, 월경주기에 따라 변하는 방사선학전 변화와 GnRH analogue 치료에 대한 극적인 증상의 호전 등의 전형적인 소견으로 폐실질 자궁내막증에 의한 catamenial hemoptysis로 진단되었다. 6회의 hormone 치료 기간동안 임상양상의 호전을 보였고, 치료를 중단한 후에도 재발의 증거가 없는 상태로 외래를 다니고 있다.

• 한국수산과학회지
• /
• 제56권3호
• /
• pp.309-314
• /
• 2023

Shark populations are constantly decreasing owing to environmental destruction and overfishing; thus, sharks are now at risk of extinction, with 30.5% of species classified as endangered on the International Union for Conservation of Nature's Red List. Sharks are apex predators and keystone species in balancing the marine food chain; their extinction would create an imbalance in the entire marine ecosystem. Assisted reproductive technology is a last resort for protecting animals facing extinction. Here, as a proactive effort toward building a hormone-induced artificial insemination protocol for endangered wild sharks, we identified the possibility of germ cell maturation by administration of GnRH, a commercially produced synthetic salmon gonadotropin-releasing hormone, and calculated its optimum dosage and injection timing. The experiment was conducted on one shark species, Chiloscyllium plagiosum. Injections were administered in 24 h intervals to C. plagiosum females, and 0.2 mL/kg+0.2 mL/kg were the optimal doses. These doses effectively induced maturation and, and ovulation, and oocyte release. Our results confirm that GnRH is a suitable tool for shark hormone-induced artificial insemination and indicate that this method may facilitate the conservation of endangered shark species.

• 한국동물학회지
• /
• 제34권4호
• /
• pp.491-499
• /
• 1991

The present experiment was carried out 1) to study the developmental topography of GnRH neuronal system and 2) to characterize the cellular localization of GnRH neurons in the prenatal brain development of the rat. At embryonic day (I) 14.5, immunoreactive cell bodies of GnRH were first seen in the nasal septum and in the ganglion terminate located in the ventral protion of the caudal olfactory bulb. Two days later (E 16.5), GnRH-containing neurons were observed at the level of olfactory tubercle and diagonal band of Broca, which is the first appearance in the intracerebral region. From 118.5, the topographic pattern of immunoreactive GnRH perikarya was similar to that of adult rats. The present data suggest that GnRH neurons were originated from the nasal septum and gradually extended to the hvpothalamic regions with increasing fetal age.

• Fisheries and Aquatic Sciences
• /
• 제3권1호
• /
• pp.37-43
• /
• 2000

We used a mammalian GnRH antagonist, $[Ac-3,4-dehydro-Pro^1,\;D-p-F-Phe^2,\;D-Trp^{3.6}]$-GnRH, to examine the details of the salmon type gonadotropin-releasing hormone (sGnRH) and GnRH agonist analog $(Des-Gly^{10}$[d-Ala^6]-ethylamide GnRH; GnRHa) functions in the control of maturational gonadotropin (GTH II) secretion, in precocious male rainbow trout, in both in vivo and in vitro experiments. In the in vivo study, plasma GTH II levels increased by sGnRH or GnRHa treatment, but the response was more rapid and stronger in the GnRHa treatment group. The increase in GTH II was significantly suppressed by the GnRH antagonist, while the antagonist had no effect on basal GTH II levels in both groups. The GnRH antagonist showed stronger suppression of GTH II levels in the sGnRH treatment fish than in the GnRHa treatment fish. In addition, plasma androgenic steroid hormones (testosterone and 11-ketotestosterone) increased by the sGnRH or GnRHa treatment. The GnRH antagonist significantly inhibited the increases in plasma androgenic steroid hormone levels stimulated by the sGnRH or GnRHa, while the antagonist had no effect on basal androgenic steroid hormone levels in both groups. In the in vitro study, treatment with sGnRH or GnRHa increased GTH II release from the cultured dispersed pituitary cells, but the response was stronger in the GnRHa treatment group. The increase in GTH II release by GnRH was suppressed by adding the GnRH antagonist, dose­dependently. On the other hand, basal release of GTH II did not decrease by the GnRH antagonist treatment in both groups. These results suggest that the GnRH antagonist, $[Ac-3,4-dehydro-Pro^1,\;D-p-F-Phe^2,\;D-Trp^{3.6}]-GnRH$, used in this study is effective in blocking the action of GnRH-induced GTH II release from the pituitary gland both in vivo and in vitro.

• 한국동물학회지
• /
• 제39권4호
• /
• pp.337-351
• /
• 1996

멜라토닌은 대뇌와 소뇌 사이에 위치한 송과선에서 분비되는 호르몬으로 빛이 없는 밤에만 분비된다. 멜라토닌은 분자적 수준에서부터 개체의 행동에 이르기 까지 다양한 기능을 보인다. 특히, 생식에 미치는 영향은 광범위하여, 온대지방에 사는 대부분의 동물은 주위 환경에 적응하여 종족을 유지하는 유일한 계절적 번식을 한다. 햄스터의 생식활동은 여름에 왕성하고 겨울에 정지된다.이는 많은 환경요소중 광주기의 효과가 송과선에 의해 제거하면 광주기의 영향은 사라진다. 즉 생식에 미치는 광주기의 효과가 송과선에 의해 중재 됨을 의미한다. 또한 송과선 호르몬인 멜라토닌의 적절한 처리는 생식활동을 억제한다. 따라서 멜라토닌은 생식에 미치는 광주기의 정보를 생식내분비계로 전달하는 신경전달물질로 사료된다. 시상하부의 특정부위를 절제한 후 광주기나 멜라토닌을 처리하여 멜라토닌의 작용부위에 관한 연구가 되었으나 동물마다 차이점을 보인다. 대부부의 동물에서 공통적인 부위는 suprachiasmatic nuclei와 pars tuberalis이다. 멜라토닌이 생식에 미치는 작용기작은 아직 밝혀지지 않았다. 이는 멜라토닌의 지속적 처리가 멜라토닌의 장기적처리는 이들 호르몬의 분비를 저하시키고, 시상하부에서의 gonadotropin-releasing hormone (GnRH)양을 증가시킨다. 이 결과는 멜라토닌의 지속적인 처리가 시상하부로부터의 GnRH 양을 분비를 감소킴으로써 생식활동을 억제하는 것으로 사료된다.그러나, 멜라토닌에서 GnRH 신경까지의 정보전달은 아직 밝혀지지 않았다. Opioid 신경에 대한 광주기와 멜라토닌의 효과가 동일한 점은 opioid신경의 매개체 역할을 제시하고 있다. 최근에 멜라토닌 수용체가 개구리의 피부와 몇몇 동물의 뇌와 시세포에서 크로닝되었다. 이수용체는 G protein과 관련되고 cAMP 생성을 억제한다. 앞으로 이 멜라토닌 수용체의 존재여부와 분자생물학적 연구는 멜라토닌의 작용부위와 표적세포에서의 작용기작을 설명하는 데 크게 기여할 것으로 기대된다.

• 한국동물학회:학술대회논문집
• /
• 한국동물학회 2003년도 한국생물과학협회 학술발표대회
• /
• pp.161.2-161
• /
• 2003

No Abstract, See Full Text

• Clinical and Experimental Reproductive Medicine
• /
• 제18권2호
• /
• pp.189-196
• /
• 1991

Long-term administration of luteinizing hormone-releasing hormone(LHRH) agonists, through a process of pituitary desensitization and down-regulation of receptors, inhibits the secretion of gonadotropin and sex-steroids and induces a reversible suppression of gonadal activity. This approach can be used as an effective endocrine therapy for some hormone-dependent tumors. We have used D-Trp6-LHRH, a long acting LHRH agonist, for the treatment of eleven patients with uterine leiomyomas, thereafter myomectomy was performed in seven cases and observed the ultrastructural changes of leiomyoma with an electron microscope. The use of LHRH agonist may be effective in reducing the size of a myoma considerably by primarily inducing medical hypophysectomy and would allow easier surgical removal. Electron microscopic findings of myoma cells after the use of LHRH agonist included the following: loss of cristae and swelling nuclear chromatin, perinuclear vacuolation in cytoplasm. Bone mineral density was slightly decreased, however, the difference was not statistically significant.

• Clinical and Experimental Reproductive Medicine
• /
• 제43권3호
• /
• pp.169-173
• /
• 2016

Objective: To determine the preferred regimen for women with adenomyosis undergoing in vitro fertilization (IVF), we compared the IVF outcomes of fresh embryo transfer (ET) cycles with or without gonadotropin-releasing hormone (GnRH) agonist pretreatment and of frozenthawed embryo transfer (FET) cycles following GnRH agonist treatment. Methods: This retrospective study included 241 IVF cycles of women with adenomyosis from January 2006 to January 2012. Fresh ET cycles without (147 cycles, group A) or with (105 cycles, group B) GnRH agonist pretreatment, and FET cycles following GnRH agonist treatment (43 cycles, group C) were compared. Adenomyosis was identified by using transvaginal ultrasound at the initial workup and classified into focal and diffuse types. The IVF outcomes were also subanalyzed according to the adenomyotic region. Results: GnRH agonist pretreatment increased the stimulation duration ($11.5{\pm}2.1days$ vs. $9.9{\pm}2.0days$) and total dose of gonadotropin ($3,421{\pm}1,141IU$ vs. $2,588{\pm}1,192IU$), which resulted in a significantly higher number of retrieved oocytes ($10.0{\pm}8.2$ vs. $7.9{\pm}6.8$, p=0.013) in group B than in group A. Controlled ovarian stimulation for freezing resulted in a significantly higher number of retrieved oocytes ($14.3{\pm}9.2$ vs. $10.0{\pm}8.2$, p=0.022) with a lower dose of gonadotropin ($2,974{\pm}1,112IU$ vs. $3,421{\pm}1,141IU$, p=0.037) in group C than in group B. The clinical pregnancy rate in group C (39.5%) tended to be higher than those in groups B (30.5%) and A (25.2%) but without a significant difference. Conclusion: FET following GnRH agonist pretreatment tended to increase the pregnancy rate in patients with adenomyosis. Further largescale prospective studies are required to confirm this result.